Antigenic Specificity of Antibody Reactive in the Antiglobulin-Augmented Lymphocytotoxicity Test

Fuller, Thomas; Phelan, D.; Gebel, Howard M.; Rodey, Glenn E.

doi:10.1097/00007890-198207000-00005

Cited by 120 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As with other centers, the histocompatibility techniques used for HLA typing, XM and detection of anti-HLA DSA in our center evolved during the study period (14)(15)(16)(17)(18)(19)(20) …”

Section: Hla Typing and Cross-match And Antibody Screening Methodsmentioning

confidence: 99%

Positive Cross-Match Living Donor Kidney Transplantation: Longer-Term Outcomes

Haririan¹,

Nogueira²,

Kukuruga

et al. 2009

American Journal of Transplantation

134

View full text Add to dashboard Cite

The long-term graft outcomes after positive crossmatch (PXM) living donor kidney transplantation (LDKT) are unknown and the descriptive published data present short-medium term results. We conducted a retrospective cohort study of LDKT with PXM by flow cytometry performed at our center during These results suggest that despite the favorable shortterm results of PXM LDKT after PP/IVIg conditioning, medium-long-term outcomes are notably worse than expected, perhaps comparable to non-ECD deceased donor kidney transplantation (KT).

show abstract

“…As with other centers, the histocompatibility techniques used for HLA typing, XM and detection of anti-HLA DSA in our center evolved during the study period (14)(15)(16)(17)(18)(19)(20) …”

Section: Hla Typing and Cross-match And Antibody Screening Methodsmentioning

confidence: 99%

Positive Cross-Match Living Donor Kidney Transplantation: Longer-Term Outcomes

Haririan¹,

Nogueira²,

Kukuruga

et al. 2009

American Journal of Transplantation

134

View full text Add to dashboard Cite

show abstract

“…18 T-lymphocyte crossmatches were performed by using the standard microlymphocytotoxic dye exclusion method with the addition of the antiglobulin technique. 19 The diagnosis of cytomegalovirus infection was based on positive blood cultures (Shell vial technique) and/or organ involvement (i.e., a positive tissue culture in association with a histologic finding of inclusion bodies).…”

Section: Methodsmentioning

confidence: 99%

Recurrence of primary sclerosing cholangitis following liver transplantation

et al. 1999

View full text Add to dashboard Cite

Recurrence of primary sclerosing cholangitis (PSC) following liver transplantation has been suggested; however, it has not been fully defined because of numerous complicating factors and the lack of diagnostic criteria. In the present study, we investigated the recurrence of PSC by developing strict criteria and applying them to a large cohort of PSC patients who underwent liver transplantation. Between March 1985 and June 1996, 150 PSC patients underwent liver transplantation at the Mayo Clinic; mean follow up was 55 months. The incidence of nonanastomotic biliary strictures and hepatic histologic findings suggestive of PSC were compared between patients transplanted for PSC and a non-PSC transplant control group. Our definition of recurrent PSC was based on characteristic cholangiographic and histologic findings that occur in nontransplant PSC patients. By using strict criteria, 30 patients with other known causes of posttransplant nonanastomotic biliary strictures were excluded leaving 120 patients for analysis of recurrence of PSC. We found evidence of PSC recurrence after liver transplantation in 24 patients (20%). Of these, 22 out of 24 patients showed characteristic features of PSC on cholangiography and 11 out of 24 had compatible hepatic histologic abnormalities with a mean time to diagnosis of 360 and 1,350 days, respectively. Both cholangiographic and hepatic histologic findings suggestive of PSC recurrence were seen in nine patients. The higher incidence and later onset of nonanastomotic biliary strictures in patients with PSC compared with a non-PSC control group is supportive of the fact that PSC does recur following liver transplantation. We were unable to identify specific clinical risk factors for recurrent PSC, and the overall patient and graft survival in patients with recurrent PSC was similar to those without evidence of recurrence. Our observations provide convincing evidence that PSC frequently recurs in the hepatic allograft using strict inclusion and exclusion criteria. (HEPATOLOGY

show abstract

“…Lymphocytotoxic antibody (LCA) testing to determine study eligibility was performed locally, and patients whose serum reacted with more than 20% of panel cells (PRA) were excluded. Plasma samples for LCA and antibody to amotosalen neoantigen testing were drawn weekly; baseline and end-of-study samples were analyzed at central laboratories for LCA by using standard techniques 31 and for antibodies to potential amotosalen neoantigens by using a validated enzyme-linked immunosorbent assay (ELISA; Cerus, Concord, CA). 28 If the patient became platelet refractory, all samples from the patient were analyzed for LCA, antibody to amotosalen neoantigens, and plateletspecific alloantibodies 32,33 in central laboratories.…”

Section: Hemostatic Assessments and Laboratory Evaluationmentioning

confidence: 99%

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

McCullough

Vesole²,

Benjamin³

et al. 2004

Blood

365

579

View full text Add to dashboard Cite

We report a transfusion trial of platelets photochemically treated for pathogen inactivation using the synthetic psoralen amotosalen HCl. Patients with thrombocytopenia were randomly assigned to receive either photochemically treated (PCT) or conventional (control) platelets for up to 28 days. The primary end point was the proportion of patients with World Health Organization (WHO) grade 2 bleeding during the period of platelet support. A total of 645 patients (318 PCT and 327 control) were evaluated. The primary end point, the incidence of grade 2 bleeding (58.5% PCT versus 57.5% control), and the secondary end point, the incidence of grade 3 or 4 bleeding (4.1% PCT versus 6.1% control), were equivalent between the 2 groups (P ‫؍‬ .001 by noninferiority). The

show abstract

Antigenic Specificity of Antibody Reactive in the Antiglobulin-Augmented Lymphocytotoxicity Test

Cited by 120 publications

References 0 publications

Positive Cross-Match Living Donor Kidney Transplantation: Longer-Term Outcomes

Positive Cross-Match Living Donor Kidney Transplantation: Longer-Term Outcomes

Recurrence of primary sclerosing cholangitis following liver transplantation

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

Contact Info

Product

Resources

About